Short online conferences at CUNY

Epidemiology and Biostatistics Forum: 3/3/21

Overview

  • Keynote: Professor Denis Nash
  • Speaker: N/A
  • Networking

 

Conference Summary

Please go here for the actual event (requires registration). The SPH Epi/Bios Conference is a forum for students, staff, alumni, faculty, and other interested attendees to learn about recent research in the CUNY community, talk to representatives of the department, school, and related institutes, and meet each other in random 1:1 networking using a full online conference platform. Make sure to register below, and contact us if you’re interested in organizing, contributing, or doing peer review for future events.

CLICK HERE FOR EVENT PAGE HERE

Program Details

Recent SARS-CoV-2 seroconversion in a national, community-based prospective cohort of U.S. adults

Epidemiological risk factors for incident SARS-CoV-2 infection are best characterized via prospective cohort studies, complementing case-based surveillance and cross-sectional seroprevalence studies. In March 2020, we launched the CHASING COVID Cohort Study, a national, community-based prospective cohort study of 6,745 U.S. adults who underwent at-home specimen collection for repeat serologic testing for SARS-CoV-2 antibodies. We identify and quantify several policy-sensitive risk factors for recent SARS-CoV-2 seroconversion, highlight persistent racial/ethnic disparities in incidence, document continued elevated risk among essential workers, and call attention to major gaps in the coverage of public health interventions aimed at testing, isolation, and contact tracing. We conclude that modifiable risk factors and poor reach of public health strategies drive SARS-CoV-2 transmission and inequities across the U.S.

Denis Nash is a Distinguished Professor of Epidemiology and the founding Executive Director of CUNY’s Institute for Implementation Science in Population Health (http://cunyisph.org). He has over 20 years of expertise in implementation science, and his research consistently generates new knowledge with clear programmatic and policy implications. His experience includes extensive domestic and international work in observational cohort studies, public health surveillance, implementation science, comparative effectiveness research and large-scale epidemiological studies examining key outcomes among persons with HIV. Dr. Nash brings seasoned expertise in study design and methodological approaches to large-scale, ‘real-world’, research projects. Prior to joining CUNY, Dr. Nash was an Epidemic Intelligence Service (EIS) Officer with the CDC and subsequently the Director of HIV/AIDS Surveillance at the New York City Department of Health, where he helped pioneer named reporting for HIV in NYC. He then joined the faculty in the Department of Epidemiology at Columbia University’s Mailman School of Public Health, where he also worked at ICAP at Columbia University as the founding Director of Monitoring, Evaluation and Research, spearheading a multi-country initiative collecting routine medical records electronically for observational cohort studies. Dr. Nash has extensive global health implementation and research experience. He has worked on large scale initiatives and research projects in sub-Saharan Africa, including on the Guinea Worm Eradication Program in Nigeria, sentinel HIV surveillance in Nigeria and Botswana, and rapid expansion/scale-up of HIV/AIDS care and treatment under the President’s Emergency Plan for AIDS Relief (PEPFAR) in Burundi, Cote d’Ivoire, Ethiopia, Kenya, Lesotho, Mozambique, Nigeria, Rwanda, South Africa, Swaziland, Tanzania, Uganda, and Zambia. Dr. Nash holds secondary faculty appointments in the Department of Epidemiology at Columbia University’s Mailman School of Public Health and in the Department of Epidemiology and Population Health at the Albert Einstein College of Medicine. He is the Principal Investigator of the CHASING COVID Cohort Study, a national, community-based prospective study of SARS-CoV-2 and other pandemic-related outcomes. 

A pre-print is available at: https://www.medrxiv.org/content/10.1101/2021.02.12.21251659v1
 

Leave a comment

Your email address will not be published. Required fields are marked *